Qualigen
Qualigen, Inc. is a biotechnology company based in Carlsbad, California, founded in 1996. The company is dedicated to developing and commercializing innovative therapeutic products aimed at treating cancer and infectious diseases. Its product offerings include the FastPack, a rapid diagnostic testing system; ALAN, a DNA-coated gold nanoparticle candidate for various cancers; AS1411, which targets viral-based infections; RAS-F3, a small-molecule inhibitor that addresses RAS mutations and tumor formation; and the STARS blood cleansing system, designed to remove tumor-produced compounds and viruses from the bloodstream. Qualigen continues to focus on advancing its diagnostic platform while expanding its range of therapeutic solutions.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. We are discovering a new frontier in human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into safe and effective applications that can have a meaningful impact on a patient’s health. Our pipeline of novel microbiome modulators selectively increase the growth of beneficial bacteria in the colonic ecosystem and create a meaningful impact on a patient’s health. Our first therapy, RP-G28, is currently under development for the treatment of lactose intolerance and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. RP-G28 has been studied in a Phase 2 clinical trial and is a first-in-class compound.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.